- Home
- GOODN vs YDESW Comparison
GOODN vs YDESW Comparison
Compare GOODN & YDESW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GOODN | YDESW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 72 | 15 |
| Industry | Real Estate | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GOODN | YDESW |
|---|---|---|
| Price | $22.21 | $0.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.3K | ★ 8.0K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.91 | $0.21 |
| 52 Week High | $23.83 | $2.85 |
Technical Indicators
Market Signals| Indicator | GOODN | YDESW |
|---|---|---|
| Relative Strength Index (RSI) | 40.53 | 37.03 |
| Support Level | $22.01 | N/A |
| Resistance Level | $22.71 | $0.36 |
| Average True Range (ATR) | 0.20 | 0.03 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 18.57 | 31.21 |
Price Performance
Historical ComparisonAbout GOODN Gladstone Commercial Corporation
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
About YDESW YD Bio Limited Warrants
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.